Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-79
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
About this trial
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are:
* Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
Eligibility criteria
Qualifiers
Aged between 18 and 79 years;
Received at least two cycles of neoadjuvant immunotherapy;
ECOG performance status score of 0;
Complete clinical information including imaging data available.
Disqualifiers
Diagnosed with or suspected active autoimmune diseases;
Presence of EGFR/ALK sensitive mutations;
Pregnant or breastfeeding women;
Previous anti-tumor therapies including chemotherapy or radiotherapy;
Trial design
Treatments tested in this trial
- Pneumonectomy
- lobectomy
- radiotherapy
- Anti-Tumor Drugs
Treatment groups
500 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov